Biotech entity
Of the tracked stories, 2 of 3 also mention Weiss Ratings, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Weiss Ratings, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline. The 62-day window averages about 0.3 stories each week. funding accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. This profile follows 3 Biotech stories mentioning Robert W. Baird across the period from July 10, 2026 to September 9, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 274 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Robert W. Baird. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
Weiss Ratings upgrades Tenaya
Weiss Ratings moved Tenaya from sell (e+) to sell (d-), still within sell territory.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Source: dailypolitical.com · tickerreport.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
Robert W. Baird is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
